| Name | Title | Contact Details |
|---|
Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma, Texas and several subsidiaries are part of the largest customer-owned health benefits company in the United States and fourth largest overall. We offer a full range of managed care programs for individuals, families, employer groups and Medicare beneficiaries. And we focus on improving the health and wellness of our members and communities by: • offering a variety of health insurance and wellness products to employers and individuals • keeping our focus local • participating in our communities in meaningful ways such as Blue Corps employee volunteer program and our Healthy Kids, Healthy Families initiative The commitment of our employees to providing superior services and products has made us one of the fastest growing health care insurance companies in the nation. Blue Cross and Blue Shield of Illinois Blue Cross and Blue Shield of Montana Blue Cross and BlueShield of New Mexico Blue Cross and Blue Shield of Oklahoma Blue Cross and Blue Shield of Texas Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. We are an Equal Opportunity Employment / Affirmative Action employer dedicated to workforce diversity and a drug-free and smoke-free workplace. Drug screening and background investigation are required, as allowed by law. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, national origin, disability, or protected veteran status.
Pharmeng Technolgy Inc. is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Atlantic Biologicals Corporation is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Charleston Laboratories Inc is a Charleston, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.